About: Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.52 (+5.71%)
PASG NASDAQ Passage Bio Inc
Passage Bio Inc share price
Atividade de preço de PASG
Último preço
$ 3,520
Variação (24h)
0,19 USD (5,71%)
Volume
16.69K
Volume (média 4 sem.)
-
Abertura
$ 3,44
Variação do dia
$ 3,33 - $ 3,83
Fechamento anterior
$ 3,33
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
PASG price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals